HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CIR Sets 2013 Review Priorities Based On Frequency Of Use

This article was originally published in The Rose Sheet

Executive Summary

Upholding its commitment to examine the cosmetic ingredients that have the most uses on the market, the Cosmetic Ingredient Review Expert Panel releases its 2013 priority list.

You may also be interested in...



CIR Nearly Finished Assessing Citrus Component Safety

Three years after initiating safety reviews of citrus substances, the Cosmetic Ingredient Review Expert Panel is on the verge of wrapping its work in the area. At its Sept. 19-20 meeting in Washington, the expert panel issued final safety assessments for six ingredient groups in total.

CIR Moves To Reopen Retinol Assessment To Examine New Data

The Cosmetic Ingredient Review Expert Panel will consider new data as it reexamines the safety of retinol and retinyl palmitate in cosmetics. Panel opts not to reopen review of triclosan or parabens.

CIR Releases 2013 Draft Review Priorities For Public Comment

The Cosmetic Ingredient Review maintains its current safety assessment approach, selecting ingredients with the highest reported uses for its 2013 draft priority list. The list is open for public comment, and will be finalized at the CIR Expert Panel’s September meeting.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018296

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel